Clinical Trial Update: Sym004 Versus TAS-102 in Patients With mCRC [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Sym004 with TAS-102 in metastatic colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Sym004
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Symphogen A/S | Conditions: Metastatic Colorectal Cancer, Colorectal Cancer Metastatic | Phase 3 | Status: WITHDRAWN